Literature DB >> 28121311

Description of Bogotá Birth Defects Surveillance and Follow-up Program.

Ignacio Zarante, Karen Sarmiento, C Mallarino, G Gracia.   

Abstract

Congenital anomalies contribute greatly to child mortality and physical disabilities. Strategies used around the world to reduce the frequency and impact of congenital anomalies require epidemiologic surveillance systems to verify their effectiveness. In Bogotá, Colombia, implementation of an accurate monitoring system has been challenging.
METHODS: The Bogotá Congenital Malformations Surveillance Program (BCMSP) gathers data on malformations from 2 sources: (1) the National Public Health Surveillance System (SIVIGILA), applying methodology from the National Health Institute, and (2) cases and control logs from hospitals.
RESULTS: Since the Secretaría Distrital de Salud was established in 2006, BCMSP has monitored 431,670 births, which have included 9,724 congenital malformations (approximately 2 percent of the cases).
CONCLUSION: This report describes the methodology of the BCMSP, and presents specific key results.

Entities:  

Mesh:

Year:  2016        PMID: 28121311

Source DB:  PubMed          Journal:  J Registry Manag        ISSN: 1945-6131


  3 in total

1.  Ophthalmic genetics in South America.

Authors:  Malena Daich Varela; Rene Moya; Patricio G Schlottmann; Robert B Hufnagel; Claudia Arberas; Federico M Fernández; M Eugenia Inga; Juliana Lores; Harry Pachajoa; Carlos E Prada; Juliana M Ferraz Sallum
Journal:  Am J Med Genet C Semin Med Genet       Date:  2020-08-28       Impact factor: 3.359

2.  Health status and barriers in health care for children with birth defects born between 2011 and 2017 in two institutions in Cali

Authors:  Luisa F Imbachi; Lina M Ibañez; Paula Hurtado-Villa
Journal:  Biomedica       Date:  2020-03-01       Impact factor: 0.935

3.  Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review.

Authors:  Juan-Sebastian Franco; David Vizcaya
Journal:  Pharmacol Res Perspect       Date:  2020-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.